Diphtheria Toxin-Epidermal Growth Factor Fusion Protein and Pseudomonas Exotoxin-Interleukin 13 Fusion Protein Exert Synergistic Toxicity against Human Glioblastoma Multiforme Cells

Bioconjugate Chemistry

Volumn 14, Issue 6, 2003, Pages 1107-1114

  Liu, Tie Fu ^a   Willingham, Mark C ^a   Tatter, Stephen B ^a   Cohen, Kimberley A ^a   Corinne Lowe, A ^a   Thorburn, Andrew ^a   Frankel, Arthur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; CELL CULTURE; CELL DEATH; CYTOTOXICITY; GROWTH KINETICS; PATIENT TREATMENT; TUMORS;

CELL KILLING; CELL LINES; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTORS; FUSION PROTEINS; GLIOBLASTOMA MULTIFORME; GLIOMA CELL LINES; HUMAN EPIDERMAL GROWTH FACTOR; INTERLEUKIN-13; SYNERGISTIC TOXICITY;

PROTEINS;

ANTINEOPLASTIC AGENT; DIPHTHERIA TOXOID; EPIDERMAL GROWTH FACTOR DERIVATIVE; HYBRID PROTEIN; INTERLEUKIN 13; PSEUDOMONAS EXOTOXIN; THYMIDINE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; CELL DEATH; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION;

PSEUDOMONAS;

EID: 0344063542     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc034111+     Document Type: Article

References (26)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. (2001) Cancer statistics, 2001. CA Cancer J. Clin. 51, 15-36.
2. Polednak, A. P. and Flannery, J. T. (1995) Brain, other central nervous system, and eye cancer. Cancer (Phila.), 75 (Suppl. 1), 330-337.
3. Glioma Meta-analysis Trialists (GMT) Group. (2002) Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-1018.
4. Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., and Herman, J. G. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354.
5. Gaspar, L. E., Fisher, B. J., Macdonald, D. R., LeBer, D. V., Halperin, E. C., Schold, S. C., and Cairncross, J. G. (1992) Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int. J. Radiat. Oncol. Biol. Phys. 24, 55-57.
6. Oldfield, E. H., Broaddus, W. C., Bruce, J., Task, T., Laske, D. W., McDonald, J., Patel, S. J., Weingart, J. D., Wharen, R. E., and Youle, R. J. (2000) Phase II trial of convection-enhanced distribution of recombinant immunotoxin in patients with recurrent malignant gliomas. Proc. Am. Assoc. Neurol. Surgeons 18, 94-95.
7. Rand, R. W., Kreitman, R. J., Patronas, N., Varricchio, F., Pastan, I., and Puri, R. K. (2000) Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res. 6, 2157-2165.
8. Prados, M. D., Lang, F. F., Strauss, L. C., Fleming, C. K., Aldape, K., Kunwar, S., Yung, W. A., Chang, S. M., Husain, S. R., Gutin, P. H., Raizer, J. J., Piepmeier, J. M., Berger, M., McDermott, M., and Puri, R. K. (2002) Intratumoral and intracerebral microinfusion of IL13-PE38QQR cytotoxin: phase I/II study of pre- and post-resection infusions in recurrent respectable malignant glioma. Proc. ASCO 21, 69b.
9. Sampson, J. R., Reardon, D., Akabani, G., Archer, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Penne, K., Paolino, A., Tourt-Uhlig, S., Quinn, J., Rich, J., Williams, R., Marcus, S., Pastan, I., and Bigner, D. D. (2002) A phase I study of intratumoral infusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α mutated form of the Pseudomonas exotoxin (TP-38) for the treatment of malignant brain tumors. Proc. ASCO 21, 13b.
10. Laske, D. W., Morrison, P. F., Lieberman, D. M., Corthesy, M. E., Reynolds, J. C., Stewart-Henney, P. A., Koong, S. S., Cummins, A., Paik, C. H., and Oldfield, E. H. (1997) Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J. Neurosurg. 87, 586-594.
11. Chou, T. C. and Talalay, P. (1983) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 4, 450-454.
12. 389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr. Pharm. Biotech. 4, 39-49.
13. Barth, S. (2001) hIL13-PE38QQR. NeoPharm. Curr. Opin. Invest. Drugs 2, 1309-1313.
14. Liu, T. F., Cohen, K. A., Willingham, M. C., Ramage, J. G., Thorburn, A. M., and Frankel, A. E. (2003) A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res. 63, 1834-1837.
15. Morgan, M. J., Thorburn, J., Thomas, L., Maxwell, T., Brothman, A. R., and Thorburn, A. (2001) An apoptosis signaling pathway induced by the death domain of FADD selectively kills normal but not cancerous prostate epithelial cells. Cell Death Differ. 8, 696-705.
16. Liu, T. F., Cohen, K. A., Willingham, M. C., Tatter, S. B., Puri, R. K., and Frankel, A. E. (2003) Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture. J. Neuro-Oncol., in press.
17. Debinski, W., Obiri, N. I., Powers, S. K., Pastan, I., and Puri, R. K. (1995) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin. Cancer Res. 1, 1253-1258.
18. Liu, T. F., Tatter, S. B., Willingham, M. C., Yang, M., Hu, J. J., and Frankel, A. E. (2003) Growth factor receptor expression varies among high grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther. 2, 783-787.
19. Yu, Y. H., Crews, J. R., Cooper, K., Ramakrishnan, S., Houston, L. L., Leslie, D. S., George, S. L., Lidor, Y., Boyer, C. M., Ring, D. B., and Bast, R. C. (1990) Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. Cancer Res. 50, 3231-3238.
20. Crews, J. R., Maier, L. A., Yu, Y. H., Hester, S., O'Briant, K., Leslie, D. S., DeSombre, K., George, S. L., Boyer, C. M., Argon, Y., and Bast, R. C. (1992) A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast cancer cell lines. Int. J. Cancer 51, 772-779.
21. Flavell, D. J., Noss, A., Pulford, K. A., Ling, N., and Flavell, S. U. (1997) Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-SAPORIN immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res. 57, 4824-4829.
22. Ghetie, M. A., Tucker, K., Richardson, J., Uhr, J. W., and Vitetta, E. S. (1994) Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 84, 702-707.
23. Flavell, D. J., Boehm, D. A., Noss, A., Warnes, S. L., and Flavell, S. U. (2001) Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Br. J. Cancer 84, 571-578.
24. Herrera, L., Farah, R. A., Pellegrini, V. A., Aquino, D. B., Sandler, E. S., Buchanan, G. R., and Vitetta, E. S. (2000) Immunotoxins against CD19 and CD22 are effective in killing precursor B acute lymphoblastic leukemia cells in vitro. Leukemia 14, 853-858.
25. Vallera, D. A., Ash, R. C., Zanjani, E. D., Kersey, J. H., LeBien, T. W., Beverley, P. C. L., Neville, D. M., and Youle, R. J. (1983) Anti-T cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science 222, 512-515.
26. Katz, F. E., Janossy, G., Cumber, A., Ross, W., Blacklock, H. A., Tax, W. and Thorpe, P. E. (1987) Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins. Br. J. Haematol. 67, 407-411.